Compare REX AI Equity Premium Income ETF (AIPI) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Dolby Laboratories, Inc. — how do they compare? REX AI Equity Premium Income ETF trades at $36.35, while Dolby Laboratories, Inc. trades at $49.6 (market cap $4.66B). The key difference: Dolby Laboratories, Inc. pays a 2.86% dividend while REX AI Equity Premium Income ETF pays none, and REX AI Equity Premium Income ETF is trading nearer its 52-week high, Dolby Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| AIPI | DLB | |
|---|---|---|
Sector | Income / Options Overlay | Industrials |
52-Week High | $44.93 | $76.79 |
52-Week Low | $32.45 | $49.31 |
Market Cap | — | $4.66B |
Enterprise Value | — | $4.12B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
DLB trades at $49.31, down 3.6% today, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected. Revenue remains stable at $1.35B for 2025, with robust gross margins of 87.44%. Recent developments include FDA progress for zervimesine in DLB psychosis and recognition as GM's 2025 Supplier of the Year.
Despite near-term technical weakness, DLB's patent-protected revenue streams and high profitability support long-term value. The consensus price target of $87.50 implies significant upside, but investors face risks from cyclical end-markets and potential dilution from drug development. The stock presents a contrarian opportunity with 47% analyst buy ratings amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
